<a href="https://laohu8.com/S/PALI">Palisade Bio Inc.</a> Introduces Phantom Equity Plan, Grants Phantom Units to Key Executives and Directors
Palisade Bio Inc. has introduced a new compensation plan involving the issuance of cash-settled phantom units to its employees, directors, and consultants. Approved by the Board of Directors on September 4, 2025, the Phantom Unit Plan allows for up to 10 million phantom units to be granted, each linked in value to the company's common stock. Under this plan, key executives, including CEO J.D. Finley, received 323,400 phantom units, while Chief Medical Officer Mitchell Jones and Senior Vice President of Finance Ryker Willie were awarded 289,000 and 137,600 units, respectively. The Board Chair and other independent directors also received allocations, solidifying the company's commitment to aligning its leadership's interests with long-term corporate performance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012687), on September 05, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。